CA2504872C - Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections - Google Patents

Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections Download PDF

Info

Publication number
CA2504872C
CA2504872C CA2504872A CA2504872A CA2504872C CA 2504872 C CA2504872 C CA 2504872C CA 2504872 A CA2504872 A CA 2504872A CA 2504872 A CA2504872 A CA 2504872A CA 2504872 C CA2504872 C CA 2504872C
Authority
CA
Canada
Prior art keywords
resveratrol
virus
influenza virus
infection
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2504872A
Other languages
English (en)
French (fr)
Other versions
CA2504872A1 (en
Inventor
Enrico Garaci
Anna Teresa Palamara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alfasigma SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of CA2504872A1 publication Critical patent/CA2504872A1/en
Application granted granted Critical
Publication of CA2504872C publication Critical patent/CA2504872C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2504872A 2002-11-06 2003-10-14 Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections Expired - Lifetime CA2504872C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000562A ITRM20020562A1 (it) 2002-11-06 2002-11-06 Uso del resveratrolo per la preparazione di un medicamento utile per il trattamento delle infezioni da virus dell'influenza.
ITRM2002A000562 2002-11-06
PCT/IT2003/000626 WO2004041260A1 (en) 2002-11-06 2003-10-14 Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections

Publications (2)

Publication Number Publication Date
CA2504872A1 CA2504872A1 (en) 2004-05-21
CA2504872C true CA2504872C (en) 2011-07-05

Family

ID=32310188

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2504872A Expired - Lifetime CA2504872C (en) 2002-11-06 2003-10-14 Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections

Country Status (18)

Country Link
US (1) US8431617B2 (https=)
EP (1) EP1567137B1 (https=)
JP (1) JP4589118B2 (https=)
KR (1) KR101060331B1 (https=)
AR (1) AR041891A1 (https=)
AT (1) ATE381929T1 (https=)
AU (1) AU2003279551A1 (https=)
CA (1) CA2504872C (https=)
CY (1) CY1107302T1 (https=)
DE (1) DE60318327T2 (https=)
DK (1) DK1567137T3 (https=)
ES (1) ES2295660T3 (https=)
IT (1) ITRM20020562A1 (https=)
MX (1) MXPA05004628A (https=)
PL (1) PL217628B1 (https=)
PT (1) PT1567137E (https=)
TW (1) TWI337863B (https=)
WO (1) WO2004041260A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1951285A2 (en) * 2005-11-18 2008-08-06 Ares Trading S.A. Interferon in influenza
EP2268272A2 (en) * 2008-03-06 2011-01-05 Mount Sinai School of Medicine of New York University Compounds that modulate negative-sense, single-stranded rna virus replication and uses thereof
WO2010053949A1 (en) * 2008-11-04 2010-05-14 Metaproteomics, Llc Phytochemical compositions and methods for activating amp-kinase
US20110236349A1 (en) * 2008-12-19 2011-09-29 Koff Jonathan L Use of Epidermal Growth Factor Inhibitors in the Treatment of Viral Infection
KR100950445B1 (ko) 2009-10-26 2010-04-02 주식회사 중앙백신연구소 감초로부터 얻은 조류, 돼지 인플루엔자 및 신종플루에 대한 항바이러스제
WO2011150413A1 (en) 2010-05-28 2011-12-01 Mount Sinai School Of Medicine Antiviral compounds and uses thereof
CA2850597A1 (en) * 2011-09-30 2013-04-04 Vanderbilt University Antiviral therapies with phospholipase d inhibitors
EP2952209B1 (en) 2014-06-04 2018-03-28 Alfasigma S.p.A. Homogeneous formulations comprising omega-3 polyunsaturated fatty acids (n-3 PUFA) and resveratrol for oral administration
EP2952180B1 (en) 2014-06-04 2017-01-25 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Solid formulations containing resveratrol and omega-3 polyunsaturated fatty acids (n-3 PUFA)
EP3120842A1 (en) * 2015-07-20 2017-01-25 Opterion Health AG Peritoneal therapeutic fluid
KR20170039456A (ko) 2015-10-01 2017-04-11 동아대학교 산학협력단 오동나무로부터 추출한 ｃ-제라닐플라보노이드계 물질을 포함하는 인플루엔자 예방 및 치료용 약학 조성물
JP2018024592A (ja) * 2016-08-09 2018-02-15 株式会社ブレインヘルス 抗生物質含有組成物
CN108893558B (zh) * 2018-05-24 2022-04-05 江苏海宏制药有限公司 一种桑木液原液抗病毒实验方法以及装置
EP4132277B1 (en) * 2020-04-05 2025-11-26 Mong, Michael Systems and methods for treating coronavirus
WO2026044308A1 (en) 2024-08-26 2026-03-05 Medizinische Universität Wien Treatment and prevention of diseases caused by influenza virus with 3,3',4,4',5,5'-hexahydroxy-trans-stilbene

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2778337B1 (fr) 1998-05-05 2001-08-31 Inst Nat Sante Rech Med Antagonistes des ligands du recepteur des arylhydrocarbures
PE20010540A1 (es) 1999-07-30 2001-05-15 Procter & Gamble Composicion de fitoalexinas estilbenicas util para la profilaxis y tratamiento de sintomas asociados con el resfriado y enfermedades similares a la influenza
DE60015568D1 (de) * 1999-08-13 2004-12-09 Univ Maryland Biotech Inst Zusammensetzungen zur behandlung von viralen infektionen und verfahren dafür

Also Published As

Publication number Publication date
JP2006507295A (ja) 2006-03-02
TW200501935A (en) 2005-01-16
TWI337863B (en) 2011-03-01
PL217628B1 (pl) 2014-08-29
JP4589118B2 (ja) 2010-12-01
KR20050071627A (ko) 2005-07-07
US20050239906A1 (en) 2005-10-27
AR041891A1 (es) 2005-06-01
CY1107302T1 (el) 2012-11-21
AU2003279551A1 (en) 2004-06-07
US8431617B2 (en) 2013-04-30
EP1567137A1 (en) 2005-08-31
ATE381929T1 (de) 2008-01-15
PT1567137E (pt) 2008-02-19
DE60318327T2 (de) 2008-12-18
CA2504872A1 (en) 2004-05-21
ES2295660T3 (es) 2008-04-16
PL377557A1 (pl) 2006-02-06
WO2004041260A1 (en) 2004-05-21
EP1567137B1 (en) 2007-12-26
ITRM20020562A1 (it) 2004-05-07
DE60318327D1 (de) 2008-02-07
MXPA05004628A (es) 2005-09-08
DK1567137T3 (da) 2008-04-28
KR101060331B1 (ko) 2011-08-30

Similar Documents

Publication Publication Date Title
CA2504872C (en) Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections
Cai et al. Inhibition of influenza infection by glutathione
Amatore et al. Influenza virus replication in lung epithelial cells depends on redox‐sensitive pathways activated by NOX4‐derived ROS
RU2769317C2 (ru) Способы лечения гриппа
Quintana et al. Antiherpes simplex virus type 2 activity of the antimicrobial peptide subtilosin
AU2020321880B2 (en) Antioxidant and antiviral compositions and methods
US20140121237A1 (en) Methods for Inhibiting Virus Replication
Jung et al. Endoplasmic reticulum-associated degradation potentiates the infectivity of influenza A virus by regulating the host redox state
Yang et al. Acute acrylonitrile exposure inhibits endogenous H2S biosynthesis in rat brain and liver: The role of CBS/3-MPST-H2S pathway in its astrocytic toxicity
Lopes et al. Serine proteases in neutrophil extracellular traps exhibit anti-Respiratory Syncytial Virus activity
US20240293384A1 (en) Methods and compositions for treatment of covid-19
Perfetto et al. In vitro antiviral and immunomodulatory activity of arbidol and structurally related derivatives in herpes simplex virus type 1-infected human keratinocytes (HaCat)
US20200230115A1 (en) Methods of treating influenza-associated viral pneumonia
Suprewicz et al. Ceragenins exhibit antiviral activity against SARS-CoV-2 by increasing the expression and release of type I interferons upon activation of the host's immune response
Yang et al. Exploration of the mechanisms of Callicarpa nudiflora Hook. et Arn against influenza A virus (H1N1) infection
RU2580305C1 (ru) ПРОТИВОВИРУСНОЕ СРЕДСТВО НА ОСНОВЕ СУХОГО ЭКСТРАКТА ЛИШАЙНИКА Cetraria islandica
Reddy et al. Neuroprotective effects of the drug GVT (monosodium luminol) are mediated by the stabilization of Nrf2 in astrocytes
Alalem et al. A novel mechanistic study on inhibiting influenza A virus replication by a newly extracted polypeptide targeting host autophagy
Kirkpatrick et al. Inducible lung epithelial resistance requires multisource reactive oxygen species generation to protect against viral infections. mBio 9: e00696-18
CN118001274B (zh) ADH-503在制备预防和/或治疗SARS-CoV-2介导的疾病的药物中的应用
RU2695336C1 (ru) Композиция на основе пептида, подавляющего репликацию вируса гриппа А
Markevičius et al. Effects of Exogenous SARS-CoV-2 S1 Protein and mRNA Vaccines on Mixed Neuronal–Glial Cell Cultures
Figueiredo et al. This is a self-archived–parallel-published version of an original article. This version may differ from the original in pagination and typographic details. When using please cite the original.
Liu et al. Infectious Bronchitis Virus Triggered Caspase-8/Casapase-3/DFNA5-Mediated Pyroptosis in HD11 Cells Via ROS
Do Rosario The mechanisms involved in the downregulation of host histone deacetylase 1 and 2 during influenza A virus infection

Legal Events

Date Code Title Description
EEER Examination request